ClinicalTrials.gg
TerminatedNCT04246203PROJECTIONUpdated Nov 17, 2026

Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer

An observational study in Pancreas Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by Ludwig-Maximilians - University of Munich. Terminated at 6 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Ludwig-Maximilians - University of Munich · Observational

How we know

Why this study was terminated
Enrollment stopped early on May 31, 2024, because of slow accrual, an unexpectedly high rate of postoperative drop-out and a low rate of ctDNA-positive patients.
Updated Nov 17, 2026Now TerminatedStart date moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
112
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 175 studies in Pancreatic Neoplasms with a site in Germany — 24 open to participants now, 35 under way, 10 of them phase 3. Pancreatic Neoplasms · Germany.

Enrollment
23rd of 29
112 · median 338
Started
2020
with 13 others
Observational
29 of 175
6 open now
Registered
123rd of 175
by date

Among the 175 studies in Pancreatic Neoplasms with a site in Germany, this one is the 23rd largest by enrollment of the 29 observational ones that give a count, is one of 14 that started in 2020, is one of 29 observational ones, and was the 123rd registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

24 of the 175 studies in Pancreatic Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 175 studies in Pancreatic Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

PROJECTION is a non-randomized, multicenter, non-interventional cohort study in patients with resectable pancreatic ductal adenocarcinoma (PDAC). Patients are allocated to two observation groups according to the preoperative presence (Group A) or absence (Group B) of circulating tumor DNA (ctDNA) in a liquid biopsy analyzed with FoundationOne Liquid CDx. After surgery and completion of local histological evaluation, tumor tissue is analyzed with FoundationOne CDx. Earlier protocol versions also included a second liquid biopsy within 14 days before the start of adjuvant chemotherapy. Patients are followed for recurrence according to institutional standards about every three months for the first 18 months after surgery and about every six months thereafter, until recurrence or death, for a maximum of 36 months after surgery and until May 31, 2025 at the latest. Enrollment was stopped on May 31, 2024.

03

Conditions studied

  • Pancreas Cancer
  • Pancreatic Ductal Adenocarcinoma

Keywords

  • circulating tumor DNA
  • liquid biopsy
  • disease-free survival
  • prognostic biomarker
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with pancreatic mass, suspicious of pancreatic cancer and deemed resectable will be prospectively enrolled in this observational study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients ≥ 18 years of age
  2. Pancreatic mass, suspicious of pancreatic cancer, deemed resectable and resection planned.
  3. Patient deemed medically fit for chemotherapy by the investigator
  4. Patient's legal capacity to consent to study participation
  5. Signed and dated to participate in the study

Exclusion criteria

Exclusion Criteria:

  1. Non-resectable disease as determined by a local tumor board
  2. pancreatic disease
  3. Previous chemotherapy
  4. Previous neoadjuvant radiotherapy
  5. Histology other than PDAC such as acinar, neuroendocrine, mixed histology etc. in the resection specimen
  6. Malignant disease other than PDAC within previous year (exception: patients with adequately treated and completely resected basal cell or squamous cell skin cancer; in situ cervical, breast or prostate cancer within previous year may be included)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
112 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Group A

    Patients are allocated to group A according to preoperative presence of detectable ctDNA.

    Diagnostic Test: FoundationOne Liquid CDx · Diagnostic Test: FoundationOne CDx

  • Group B

    Patients are allocated to group B according to preoperative absence of detectable ctDNA.

    Diagnostic Test: FoundationOne Liquid CDx · Diagnostic Test: FoundationOne CDx

Interventions

  • Diagnostic testFoundationOne Liquid CDx

    Liquid biopsy of about 17-20 ml peripheral blood within 7 days (in exceptional cases 14 days) before surgery; analysis of circulating tumor DNA with FoundationOne Liquid CDx. Results were not reported to investigators and did not influence treatment.

  • Diagnostic testFoundationOne CDx

    Genomic profiling of formalin-fixed, paraffin-embedded tumor tissue from the resection specimen with FoundationOne CDx.

06

What researchers measure

Primary outcomes

  1. Disease-free survival (DFS)

    Comparison of disease-free survival (DFS) between patients with preoperative presence (Group A) and absence (Group B) of circulating tumor DNA. DFS is the time from surgery to local recurrence, distant metastasis or death from any cause, whichever comes first.

    Time frame: From surgery until recurrence or death, up to 36 months after surgery and no later than May 31, 2025

Secondary outcomes

  1. DFS by tumor mutational status

    DFS in Groups A and B according to the mutational status of the resected tumor tissue determined with FoundationOne CDx

    Time frame: From surgery until recurrence or death, up to 36 months after surgery and no later than May 31, 2025

  2. DFS by clinical parameters

    DFS in Groups A and B according to clinical parameters

    Time frame: From surgery until recurrence or death, up to 36 months after surgery and no later than May 31, 2025

Other outcomes

  1. Overall survival (OS)

    Time from surgery to death from any cause, compared between Groups A and B

    Time frame: From surgery until death or end of observation, no later than May 31, 2025

07

Study locations

6 sites
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual participant data are available on reasonable request to the corresponding author after review by the study leadership and under a data use agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2020 to primary completion in Jun 2025, 53 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: start Dec 2021 → Dec 2020, primary completion Dec 2025 → Jun 2025 and completion Dec 2026 → Jun 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2020
First posted
Jan 29, 2020
StartActual
Dec 22, 2020was Dec 2021
Primary completionActual
Jun 2, 2025was Dec 2025
CompletionActual
Jun 2, 2025was Dec 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Enrollment stopped early on May 31, 2024, because of slow accrual, an unexpectedly high rate of postoperative drop-out and a low rate of ctDNA-positive patients.
changed Nov 17, 2026
Start date
Dec 12, 2021→Dec 22, 2020
Nov 17, 2026
Primary completion
Dec 1, 2025→Jun 2, 2025 (actual)
Nov 17, 2026
Study completion
Dec 1, 2026→Jun 2, 2025 (actual)
Nov 17, 2026
Enrollment
200 (estimated)→112 (actual)
Nov 17, 2026
Interventions
Added Diagnostic test: FoundationOne Liquid CDx·Diagnostic test: FoundationOne CDx; removed Liquid Biopsy
Nov 17, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore DFSNow Disease-free survival (DFS)Time frame: Follow up will be 36 months after surgery. → From surgery until recurrence or death, up to 36 months after surgery and no later than May 31, 2025
Nov 17, 2026
Secondary outcomes
3 added
What changed in the outcomes
  • AddedDFS by tumor mutational statusTime frame: From surgery until recurrence or death, up to 36 months after surgery and no later than May 31, 2025
  • AddedDFS by clinical parametersTime frame: From surgery until recurrence or death, up to 36 months after surgery and no later than May 31, 2025
  • Addedother outcomeOverall survival (OS)Time frame: From surgery until death or end of observation, no later than May 31, 2025
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Active, not recruiting→Terminated
    Why stopped Enrollment stopped early on May 31, 2024, because of slow accrual, an unexpectedly high rate of postoperative drop-out and a low rate of ctDNA-positive patients.
    Start date Dec 12, 2021→Dec 22, 2020
    Primary completion Dec 1, 2025→Jun 2, 2025 (now actual)
    Study completion Dec 1, 2026→Jun 2, 2025 (now actual)
    Enrollment 200 (estimated)→112 (actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore DFSNow Disease-free survival (DFS)Time frame: Follow up will be 36 months after surgery. → From surgery until recurrence or death, up to 36 months after surgery and no later than May 31, 2025
    Secondary outcomes 3 added
    What changed in the outcomes
    • AddedDFS by tumor mutational statusTime frame: From surgery until recurrence or death, up to 36 months after surgery and no later than May 31, 2025
    • AddedDFS by clinical parametersTime frame: From surgery until recurrence or death, up to 36 months after surgery and no later than May 31, 2025
    • Addedother outcomeOverall survival (OS)Time frame: From surgery until death or end of observation, no later than May 31, 2025
    Interventions Added Diagnostic test: FoundationOne Liquid CDx·Diagnostic test: FoundationOne CDx; removed Liquid Biopsy
    + 8 other changes: verification date, oversight details, description, conditions, design details, site details, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04246203
Collaborators
Hoffmann-La Roche
Responsible party
Benedikt Westphalen (Principal Investigator, Ludwig-Maximilians - University of Munich) — Principal investigator
First posted
Jan 29, 2020
Start date
Dec 22, 2020
Primary completion
Jun 2, 2025
Completion
Jun 2, 2025
Last update
Nov 17, 2026

Study contacts

Benedikt Westphalen
principal investigator · LMU Munich

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion